Patrick Sanders

Patrick Sanders

Expertise: Tech stocks, Bank stocks, Buy-and-hold investing

Expertise:

Tech stocks
Bank stocks
Buy-and-hold investing

Education:

Graduate of Marshall University

About Patrick:

Patrick Sanders is a freelance writer, editor and stock market expert. He is founding editor of Invested, a daily stock market newsletter published by U.S. News & World Report, and he managed U.S. News’ investing advice section from 2015 to 2019.

He previously was deputy managing editor of InvestorPlace.com. He operated news websites in southeast Europe and Turkey, was the founding managing editor of the New York Times Editing Center and was Connecticut news editor for The Associated Press.

Patrick has made numerous media appearances as a stock market analyst and appeared on panels to discuss personal finance and investing. He served on the board of governors of the Society for Advancing Business Editing and Writing, and was co-chairman of the training committee to promote and develop training opportunities for business journalists throughout North America.

Patrick is a graduate of Marshall University and now resides in Maryland. Follow him on Twitter or connect on LinkedIn.

Recent Articles

Why Long-Suffering Alibaba Stock Is a Screaming Buy

Alibaba was wounded but not permanently damaged by Beijing's crackdown. BABA stock now shows signs of life while selling at a huge discount.

ContextLogic Is a David vs. Goliath Tale That Ends Poorly

On one level, it's easy to root for ContextLogic as a legitimate competitor to Amazon. But in the end, WISH stock has no chance.

Ethereum Upgrade Makes it More Attractive Than Bitcoin

Ethereum dwarfs Bitcoin's gains over the past year, and its ongoing Ethereum 2.0 upgrade should help push the coin into the mainstream.

5 Bank Stocks To Buy for an Earnings Bump as Reporting Season Kicks Off

These five bank stocks should exceed their earnings per share posted a year ago, and they all have an edge over the biggest banks in the U.S.

Without a Partner, iBio’s Gains Are Just a Fantasy

iBio is behind others in developing a Covid-19 vaccine and it doesn't have a FastPharming partner. There's diminishing value to IBIO stock.